Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on May 27, 2025
SciSparc Announces Publication of Japanese Patent Application
GlobeNewswire
·
May 27, 2025
TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central …
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
GlobeNewswire
·
May 27, 2025
Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and …
Evaxion announces business update and first quarter 2025 financial results
GlobeNewswire
·
May 27, 2025
COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2025 financial results. Business …
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
GlobeNewswire
·
May 27, 2025
Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage setting Phase 1/2 study has now transitioned to dosing patients in combination with checkpoint inhibitor in metastatic breast cancer First Bria-OTS monotherapy patient …
Adagene to Present at Jefferies Global Healthcare Conference 2025
GlobeNewswire
·
May 27, 2025
SAN DIEGO and SUZHOU, China, May 27, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chief Strategy Officer, Mickael …
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
GlobeNewswire
·
May 27, 2025
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 …
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
GlobeNewswire
·
May 27, 2025
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced a strategic collaboration to …
Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report
GlobeNewswire
·
May 27, 2025
WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related …
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease
GlobeNewswire
·
May 27, 2025
MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration (U.S. FDA) …
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2…
GlobeNewswire
·
May 27, 2025
CANOPY assessed pemivibart safety and tolerability, antiviral immunobridging, and exploratory efficacy against COVID-19, and is the only clinical trial of an authorized or approved COVID-19 monoclonal antibody or vaccine with placebo-controlled clinical …
BioCryst to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 27, 2025
RESEARCH TRIANGLE PARK, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: Jefferies Global Healthcare Conference in New York on Wednesday, …
EDAP to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 27, 2025
AUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings …
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
GlobeNewswire
·
May 27, 2025
BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 46th Annual …
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
GlobeNewswire
·
May 27, 2025
NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the Nasdaq Hearings Panel …
See All AI Raises $33 Million to Bring Revolutionary AI-Based Sliceable Intraoperative 3D Visualization and Advanced Navigation to Global Healthcare
GlobeNewswire
·
May 27, 2025
NASHUA, N.H., May 27, 2025 (GLOBE NEWSWIRE) -- See All AI (the “Company”), a pioneering company leveraging artificial intelligence, deep learning, and machine vision for intraoperative 3D surgical imaging and navigation, announced today that it has closed …
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
GlobeNewswire
·
May 27, 2025
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced the Company will be presenting new exploratory biomarker data from its SER-155 Phase …
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
GlobeNewswire
·
May 27, 2025
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement …
Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer
GlobeNewswire
·
May 27, 2025
Mr. DaFonseca Possesses Nearly 30 Years of Broad Drug Development Experience, including More than 15 Years Leading High Performing CDMO Sales Organizations Will Leverage Deep Pharma Services Expertise as Leader of Lifecore’s Sales Organization Focused on …
GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases
GlobeNewswire
·
May 27, 2025
Financing led by Novo Holdings with significant support from world-class group of existing and new investors Proceeds from financing to support development of first-in-class IgG4-targeted protein degrader program through clinical proof-of-concept and the …
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
·
May 27, 2025
BOSTON and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or …